All Clarivate websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.
U.S. Worldmeds LLC's Lucemyra (lofexidine) moved another step closer to the U.S. market Tuesday with an 11-1 advisory committee vote recommending FDA approval of the drug to mitigate symptoms of opioid withdrawal.